Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 7/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3805924 | 0.97 | TSHR (0.48) | TSHRALDH1A1TP53PAOXTERT | |
| SCHEMBL25529753 | 0.85 | ALDH1A1 (0.54) | TSHRALDH1A1TP53PAOXAPOBEC3A | |
| Hydrochloric Acid SCHEMBL31326634 | 0.83 | ALDH1A1 (0.52) | TSHRALDH1A1TP53PAOXAPOBEC3A | |
| SCHEMBL1771780 | 0.81 | ALDH1A1 (0.58) | TSHRALDH1A1TP53PAOXAPOBEC3A | |
| SCHEMBL8517701 | 0.79 | TSHR (0.74) | TSHRALDH1A1TP53LMNACA12 | |
| SCHEMBL27854645 | 0.78 | PAOX (0.41) | TSHRALDH1A1PAOXTERTAPOBEC3A | |
| SCHEMBL3624629 | 0.77 | TSHR (0.48) | TSHRALDH1A1TP53LMNACHRM2 | |
| SCHEMBL12652504 | 0.77 | PAOX (0.34) | TSHRALDH1A1TP53PAOXTERT | |
| SCHEMBL105467 | 0.76 | KDM5A (0.48) | TSHRALDH1A1PAOXMEN1KMT2A | |
| SCHEMBL5255803 | 0.76 | PAOX (0.39) | TSHRALDH1A1PAOXTERTAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049948-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-118829625-A | Novel ionizable lipids and lipid nanoparticles and methods of use thereof | 赛欧生物医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4433450-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023091490-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088308-A1 | ANTIMICROBIAL COMPOUND HAVING ANTI-DRUG RESISTANCE | 石家庄迪斯凯威医药科技有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091490-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| CN-116135871-A | Antibacterial compound with drug resistance | 石家庄迪斯凯威医药科技有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-109456328-B | 11-substituted 1, 6-diazabenzanthrone derivative and synthesis method and application thereof | GUANGXI NORMAL UNIVERSITY (CN) | 2021-06-22 | — | — | CN | disclosed |
| CN-109438445-B | 8-substituted 1, 6-diazabenzanthrone derivative and synthesis method and application thereof | GUANGXI NORMAL UNIVERSITY (CN) | 2021-06-22 | — | — | CN | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| WO-2008012603-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DIFLUNISAL AND RELATED COMPOUNDS WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-31 | — | — | WO | disclosed |
| EP-1778669-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | TSHR 1322/4885ALDH1A1 4393/4885TP53 541/4885 |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | TSHR 3783/4885ALDH1A1 741/4885TP53 431/4885 |
| US-20250049948-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | NPC1L1, ABCB4, LIPA | TSHR 3809/4885ALDH1A1 4108/4885TP53 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.